Cargando…

Preclinical evaluation of safety and potential of black hellebore extracts for cancer treatment

BACKGROUND: The therapeutic use of Helleborus niger L. is manifold due to its specific phytochemical composition. Two compound groups, the ranunculin derivates including protoanemonin and the steroidal saponins, are also associated with toxicity (genotoxicity, disintegration of membrane structures)....

Descripción completa

Detalles Bibliográficos
Autores principales: Felenda, Jennifer E., Turek, Claudia, Mörbt, Nora, Herrick, Anja, Müller, Margit B., Stintzing, Florian C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528284/
https://www.ncbi.nlm.nih.gov/pubmed/31113420
http://dx.doi.org/10.1186/s12906-019-2517-5
_version_ 1783420183393599488
author Felenda, Jennifer E.
Turek, Claudia
Mörbt, Nora
Herrick, Anja
Müller, Margit B.
Stintzing, Florian C.
author_facet Felenda, Jennifer E.
Turek, Claudia
Mörbt, Nora
Herrick, Anja
Müller, Margit B.
Stintzing, Florian C.
author_sort Felenda, Jennifer E.
collection PubMed
description BACKGROUND: The therapeutic use of Helleborus niger L. is manifold due to its specific phytochemical composition. Two compound groups, the ranunculin derivates including protoanemonin and the steroidal saponins, are also associated with toxicity (genotoxicity, disintegration of membrane structures). Therefore, in vitro investigations were performed on safety aspects of a Helleborus niger aqueous fermented extract (HNE). In addition its therapeutic potential against various cancer cell lines was assessed to gain insight into the respective mechanisms of action. METHODS: To evaluate the safe use of HNE, Ames and hemolytic tests were carried out. Two angiogenesis assays in 2D and 3D design were conducted to assess the anti-angiogenetic potential, for which human umbilical vein endothelial cells (HUVEC) were chosen. A panel of tumor cell lines was used in 2D and 3D proliferation assays as well in the migration- and invasion-assay. All investigations were performed with HNE compared to reference substances. The 2D proliferation assay was additionally performed with isolated compounds of HNE (characteristic steroidal saponins). RESULTS: HNE did not exhibit any genotoxic potential. Concentrations up to 10 μl/ml were classified as non-hemolytic. HNE exerted anti-angiogenetic effects in HUVEC and anti-proliferative effects in five cancer cell lines, whereas hellebosaponin A and D as well macranthosid I did not show comparable effects neither singly nor in combination. Due to the inherent instability of protoanemonin in isolated form, parallel investigations with protoanemonin could not be performed. HNE (600–1000 μg/ml) inhibited the migration of certain cancer cells by > 80% such as Caki-2, DLD-1 and SK-N-SH. CONCLUSION: HNE exhibit neither genotoxic nor hemolytic potential. The present investigations verify the anti-angiogenetic effects on HUVEC, the anti-proliferative effects and migration-inhibiting properties on tumor cells. The lower effect of the relevant steroidal saponins compared to the whole extract underlines the fact that the latter is more effective than a blend of isolated pharmacologically active components. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12906-019-2517-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6528284
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65282842019-05-28 Preclinical evaluation of safety and potential of black hellebore extracts for cancer treatment Felenda, Jennifer E. Turek, Claudia Mörbt, Nora Herrick, Anja Müller, Margit B. Stintzing, Florian C. BMC Complement Altern Med Research Article BACKGROUND: The therapeutic use of Helleborus niger L. is manifold due to its specific phytochemical composition. Two compound groups, the ranunculin derivates including protoanemonin and the steroidal saponins, are also associated with toxicity (genotoxicity, disintegration of membrane structures). Therefore, in vitro investigations were performed on safety aspects of a Helleborus niger aqueous fermented extract (HNE). In addition its therapeutic potential against various cancer cell lines was assessed to gain insight into the respective mechanisms of action. METHODS: To evaluate the safe use of HNE, Ames and hemolytic tests were carried out. Two angiogenesis assays in 2D and 3D design were conducted to assess the anti-angiogenetic potential, for which human umbilical vein endothelial cells (HUVEC) were chosen. A panel of tumor cell lines was used in 2D and 3D proliferation assays as well in the migration- and invasion-assay. All investigations were performed with HNE compared to reference substances. The 2D proliferation assay was additionally performed with isolated compounds of HNE (characteristic steroidal saponins). RESULTS: HNE did not exhibit any genotoxic potential. Concentrations up to 10 μl/ml were classified as non-hemolytic. HNE exerted anti-angiogenetic effects in HUVEC and anti-proliferative effects in five cancer cell lines, whereas hellebosaponin A and D as well macranthosid I did not show comparable effects neither singly nor in combination. Due to the inherent instability of protoanemonin in isolated form, parallel investigations with protoanemonin could not be performed. HNE (600–1000 μg/ml) inhibited the migration of certain cancer cells by > 80% such as Caki-2, DLD-1 and SK-N-SH. CONCLUSION: HNE exhibit neither genotoxic nor hemolytic potential. The present investigations verify the anti-angiogenetic effects on HUVEC, the anti-proliferative effects and migration-inhibiting properties on tumor cells. The lower effect of the relevant steroidal saponins compared to the whole extract underlines the fact that the latter is more effective than a blend of isolated pharmacologically active components. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s12906-019-2517-5) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-21 /pmc/articles/PMC6528284/ /pubmed/31113420 http://dx.doi.org/10.1186/s12906-019-2517-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Felenda, Jennifer E.
Turek, Claudia
Mörbt, Nora
Herrick, Anja
Müller, Margit B.
Stintzing, Florian C.
Preclinical evaluation of safety and potential of black hellebore extracts for cancer treatment
title Preclinical evaluation of safety and potential of black hellebore extracts for cancer treatment
title_full Preclinical evaluation of safety and potential of black hellebore extracts for cancer treatment
title_fullStr Preclinical evaluation of safety and potential of black hellebore extracts for cancer treatment
title_full_unstemmed Preclinical evaluation of safety and potential of black hellebore extracts for cancer treatment
title_short Preclinical evaluation of safety and potential of black hellebore extracts for cancer treatment
title_sort preclinical evaluation of safety and potential of black hellebore extracts for cancer treatment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6528284/
https://www.ncbi.nlm.nih.gov/pubmed/31113420
http://dx.doi.org/10.1186/s12906-019-2517-5
work_keys_str_mv AT felendajennifere preclinicalevaluationofsafetyandpotentialofblackhelleboreextractsforcancertreatment
AT turekclaudia preclinicalevaluationofsafetyandpotentialofblackhelleboreextractsforcancertreatment
AT morbtnora preclinicalevaluationofsafetyandpotentialofblackhelleboreextractsforcancertreatment
AT herrickanja preclinicalevaluationofsafetyandpotentialofblackhelleboreextractsforcancertreatment
AT mullermargitb preclinicalevaluationofsafetyandpotentialofblackhelleboreextractsforcancertreatment
AT stintzingflorianc preclinicalevaluationofsafetyandpotentialofblackhelleboreextractsforcancertreatment